Next Article in Journal
Establishment of an Artificial Neural Network Model Using Immune-Infiltration Related Factors for Endometrial Receptivity Assessment
Next Article in Special Issue
Capturing a Crucial ‘Disorder-to-Order Transition’ at the Heart of the Coronavirus Molecular Pathology—Triggered by Highly Persistent, Interchangeable Salt-Bridges
Previous Article in Journal
The Course of Anti-HBc Antibodies over Time in Immunocompromised Hosts
Previous Article in Special Issue
How Does Severe Acute Respiratory Syndrome-Coronavirus-2 Affect the Brain and Its Implications for the Vaccines Currently in Use

Plant-Based Vaccines in Combat against Coronavirus Diseases

Institute of Plant Genetics, Polish Academy of Sciences, Strzeszyńska 34, 60-479 Poznań, Poland
Author to whom correspondence should be addressed.
Academic Editor: Sankar Basu
Vaccines 2022, 10(2), 138;
Received: 4 December 2021 / Revised: 6 January 2022 / Accepted: 14 January 2022 / Published: 18 January 2022
(This article belongs to the Special Issue Coronavirus: Vaccines and Other Therapeutics)
Coronavirus (CoV) diseases, including Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) have gained in importance worldwide, especially with the current COVID-19 pandemic caused by SARS-CoV-2. Due to the huge global demand, various types of vaccines have been developed, such as more traditional attenuated or inactivated viruses, subunit and VLP-based vaccines, as well as novel DNA and RNA vaccines. Nonetheless, emerging new COVID-19 variants are necessitating continuous research on vaccines, including these produced in plants, either via stable expression in transgenic or transplastomic plants or transient expression using viral vectors or agroinfection. Plant systems provide low cost, high scalability, safety and capacity to produce multimeric or glycosylated proteins. To date, from among CoVs antigens, spike and capsid proteins have been produced in plants, mostly using transient expression systems, at the additional advantage of rapid production. Immunogenicity of plant-produced CoVs proteins was positively evaluated after injection of purified antigens. However, this review indicates that plant-produced CoVs proteins or their carrier-fused immunodominant epitopes can be potentially applied also as mucosal vaccines, either after purification to be administered to particular membranes (nasal, bronchus mucosa) associated with the respiratory system, or as oral vaccines obtained from partly processed plant tissue. View Full-Text
Keywords: coronaviruses; COVID-19; MERS-CoV; SARS-CoV; biopharming; plant-based vaccines coronaviruses; COVID-19; MERS-CoV; SARS-CoV; biopharming; plant-based vaccines
Show Figures

Figure 1

MDPI and ACS Style

Ortega-Berlanga, B.; Pniewski, T. Plant-Based Vaccines in Combat against Coronavirus Diseases. Vaccines 2022, 10, 138.

AMA Style

Ortega-Berlanga B, Pniewski T. Plant-Based Vaccines in Combat against Coronavirus Diseases. Vaccines. 2022; 10(2):138.

Chicago/Turabian Style

Ortega-Berlanga, Benita, and Tomasz Pniewski. 2022. "Plant-Based Vaccines in Combat against Coronavirus Diseases" Vaccines 10, no. 2: 138.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop